We are live on ! Find out more
Baillie Gifford & Co

Baillie Gifford & Co Portfolio holdings

AUM $110B
1-Year Est. Return 4.8%
 

Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.

This Fund
S&P 500
This Quarter Est. Return
+34.19%
1 Year Est. Return
+4.8%
3 Year Est. Return
+123.53%
5 Year Est. Return
+125.55%
10 Year Est. Return
+1,754.37%
AUM
$180B
AUM Growth
+$34.5B
Cap. Flow
+$124M
Cap. Flow %
0.07%
Top 10 Hldgs %
43.41%
Holding
443
New
192
Increased
135
Reduced
77
Closed
14

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$1.73B
2
ONC
BeOne Medicines Ltd
ONC
+$774M
3
ILMN icon
Illumina
ILMN
+$691M
4
DXCM icon
DexCom
DXCM
+$438M
5
NFLX icon
Netflix
NFLX
+$360M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 37.71%
2 Technology 16.18%
3 Healthcare 15.43%
4 Communication Services 14.41%
5 Financials 5.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
XENT
401
DELISTED
Intersect ENT, Inc
XENT
$8K ﹤0.01%
+340
New +$6.47K
CMPR icon
402
Cimpress
CMPR
$2.31B
$7K ﹤0.01%
+80
New +$6.87K
HI
403
DELISTED
Hillenbrand
HI
$7K ﹤0.01%
+167
New +$5.76K
HRTX icon
404
Heron Therapeutics
HRTX
$92.9M
$7K ﹤0.01%
+326
New +$5.67K
INGN icon
405
Inogen
INGN
$164M
$7K ﹤0.01%
+149
New +$5.14K
MOD icon
406
Modine Manufacturing
MOD
$10.4B
$7K ﹤0.01%
+558
New +$5.41K
WLY icon
407
John Wiley & Sons Class A
WLY
$2.66B
$7K ﹤0.01%
+159
New +$5.76K
WSM icon
408
Williams-Sonoma
WSM
$29.6B
$7K ﹤0.01%
+136
New +$6.96K
ATEX icon
409
Anterix
ATEX
$1.94B
$6K ﹤0.01%
+162
New +$5.34K
BMRN icon
410
BioMarin Pharmaceuticals
BMRN
$12.4B
$6K ﹤0.01%
+74
New +$5.87K
ZYXI
411
DELISTED
Zynex
ZYXI
$6K ﹤0.01%
+481
New +$6.26K
ATRI
412
DELISTED
Atrion Corp
ATRI
$6K ﹤0.01%
+9
New +$5.59K
POLY
413
DELISTED
Plantronics, Inc.
POLY
$6K ﹤0.01%
+234
New +$5.13K
MDP
414
DELISTED
Meredith Corporation
MDP
$6K ﹤0.01%
+320
New +$5.2K
AGX icon
415
Argan
AGX
$8.37B
$5K ﹤0.01%
+103
New +$4.62K
OXM icon
416
Oxford Industries
OXM
$552M
$5K ﹤0.01%
+82
New +$4.24K
QTTB icon
417
Q32 Bio
QTTB
$464M
$5K ﹤0.01%
+27
New +$5.22K
EXTR icon
418
Extreme Networks
EXTR
$3.15B
$4K ﹤0.01%
+588
New +$3.16K
HCSG icon
419
Healthcare Services Group
HCSG
$1.53B
$4K ﹤0.01%
+153
New +$3.7K
MDXG icon
420
MiMedx Group
MDXG
$633M
$4K ﹤0.01%
+484
New +$3.48K
ALKS icon
421
Alkermes
ALKS
$8.25B
$3K ﹤0.01%
+155
New +$2.84K
AXDX
422
DELISTED
Accelerate Diagnostics
AXDX
$3K ﹤0.01%
+37
New +$3.31K
PBYI icon
423
Puma Biotechnology
PBYI
$454M
$3K ﹤0.01%
+252
New +$2.55K
VRAY
424
DELISTED
ViewRay, Inc.
VRAY
$3K ﹤0.01%
+803
New +$2.84K
AAOI icon
425
Applied Optoelectronics
AAOI
$11.5B
$2K ﹤0.01%
+260
New +$2.37K

Similar funds

Baillie Gifford & Co's Q4 2020 Portfolio in Review

As of Q4 2020, Baillie Gifford & Co held 443 positions worth $180B, up 24% from $145B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Baillie Gifford & Co's Q4 2020 filing shows 192 new, 135 increased, 77 reduced and 14 closed positions. Its largest new stake was Kingsoft Cloud Holdings: 7,346,496 shares worth $320M. The largest sale was Tesla, an estimated $3.79B.

By sector, the portfolio is most concentrated in Consumer Discretionary at 38% of assets, up from 37% a quarter earlier, followed by Technology and Healthcare.

  • Baillie Gifford & Co's largest Q4 2020 buy was Kingsoft Cloud Holdings: 7,346,496 shares worth $320M.
  • Baillie Gifford & Co added most to Moderna in Q4 2020, an estimated $1.73B increase.
  • Baillie Gifford & Co's biggest Q4 2020 reduction was Tesla, cutting an estimated $3.79B.
  • Baillie Gifford & Co fully exited TD Ameritrade Holding Corp in Q4 2020, selling an estimated $264M.
  • Baillie Gifford & Co's ten largest holdings make up 43% of its $180B portfolio in Q4 2020.
  • Baillie Gifford & Co opened 192 new positions and closed 14 in Q4 2020.
  • Baillie Gifford & Co's portfolio value rose 24% quarter-over-quarter to $180B.

Based on Baillie Gifford & Co's 13F filing for Q4 2020, filed 10 Feb 2021.